Source:http://linkedlifedata.com/resource/pubmed/id/12204873
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2002-9-2
|
| pubmed:abstractText |
The pathophysiology of asthma involves an intricate network of molecular and cellular interactions. Elevated Th2 cytokines (interleukin [IL]-5 and IL-4) associated with eosinophilic inflammation characterize allergic diseases and provide potential targets for immunomodulation. Recent evidence has demonstrated that galectin-3 induces selective downregulation of IL-5 gene expression in several cell types (eosinophils, T cell lines, and antigen specific T cells). Accordingly, we sought to elucidate whether in vivo intratracheal instillation of plasmid DNA encoding galectin-3 would inhibit an experimental asthmatic reaction in a rat model with increased eosinophils and T cells in bronchoalveolar fluid and impaired pulmonary function. We found that instillation of galectin-3 gene in these rats led to normalization of the eosinophil and T cell count in bronchoalveolar lavage fluid and that there was a strong concomitant inhibition of IL-5 mRNA in the lungs. As a consequence, galectin-3-treated rats showed recovery of pulmonary functional parameters, such as pulmonary pressure and expiratory flows. These data emphasize the potential utility of galectin-3 as a novel therapeutic approach for treatment of allergic asthma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1073-449X
|
| pubmed:author |
pubmed-author:CárdabaBlancaB,
pubmed-author:CivantosEstherE,
pubmed-author:CorteganoIsabelI,
pubmed-author:GallardoSoledadS,
pubmed-author:González-MangadoNicolasN,
pubmed-author:LópezEstherE,
pubmed-author:LahozCarlosC,
pubmed-author:Martín-MosqueroCarmenC,
pubmed-author:OrtegaMercedesM,
pubmed-author:PalominoPilarP,
pubmed-author:Peces-BarbaGermánG,
pubmed-author:RojoMartaM,
pubmed-author:RubioMaria LML,
pubmed-author:del PozoVictoriaV
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
166
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
732-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12204873-Airway Obstruction,
pubmed-meshheading:12204873-Animals,
pubmed-meshheading:12204873-Antigens,
pubmed-meshheading:12204873-Antigens, Differentiation,
pubmed-meshheading:12204873-Asthma,
pubmed-meshheading:12204873-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:12204873-Disease Models, Animal,
pubmed-meshheading:12204873-Down-Regulation,
pubmed-meshheading:12204873-Galectin 3,
pubmed-meshheading:12204873-Gene Therapy,
pubmed-meshheading:12204873-Immunoblotting,
pubmed-meshheading:12204873-Interleukin-5,
pubmed-meshheading:12204873-Male,
pubmed-meshheading:12204873-Polymerase Chain Reaction,
pubmed-meshheading:12204873-Random Allocation,
pubmed-meshheading:12204873-Rats,
pubmed-meshheading:12204873-Rats, Inbred BN,
pubmed-meshheading:12204873-Reference Values,
pubmed-meshheading:12204873-Respiratory Function Tests,
pubmed-meshheading:12204873-Sensitivity and Specificity
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation.
|
| pubmed:affiliation |
Immunology Department, Fundación Jiménez Díaz, Madrid, Spain.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|